Inozyme Pushes Boundaries in Treating Rare Diseases at Global Healthcare Conference

Introduction to Inozyme Pharma

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing innovative treatments for rare diseases. These diseases often involve abnormal mineral deposits and tissue proliferation within the body, leading to severe health issues.

Upcoming Presentation at Jefferies Global Healthcare Conference

The CEO and Chairman of Inozyme, Doug Treco, Ph.D., will be sharing the company's progress and vision at the Jefferies Global Healthcare Conference. The presentation, scheduled for June 6, 2024, will offer insights into their latest therapeutic advancements.

About INZ-701

One of the key focus areas for Inozyme is the development of INZ-701, an enzyme replacement therapy. This therapy aims to treat conditions caused by excessive mineral deposition and uncontrolled cell growth, which are often fatal.

Disease Focus

Inozyme focuses on treating ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. These are severe diseases characterized by abnormal mineralization and tissue proliferation that can significantly impact patients' quality of life.

Clinical Progress

INZ-701 is currently in the clinical development stages, bringing hope to patients suffering from these debilitating conditions. Early studies indicate promising results in reducing the detrimental effects of abnormal mineral deposits.

Impact of Pathologic Mineralization

Pathologic mineralization involves the buildup of minerals in tissues where they do not belong. This can lead to various health issues, including cardiovascular problems and skeletal deformities.

Innovative Solutions

Inozyme’s innovative approach aims to address these challenges at the molecular level, potentially offering life-changing treatments for affected patients. The enzyme replacement therapy could help mitigate the severe consequences of these rare diseases.

Accessing the Presentation

For those interested, the live webcast of the presentation can be accessed through the Investor Relations section of Inozyme’s website. A replay will also be available for a limited time after the event.

Contact Information

For further inquiries, investors can reach out to Stefan Riley, the Senior Director of IR and Corporate Communications at Inozyme Pharma. Media inquiries can be directed to Matt Pera at SmithSolve.